Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CAPECITABINE

All products: general benefit

Other products in the same Health Canada class (L01B, L01BC) — coverage varies; not interchangeable

  • Fluorouracil + salicylic acid (Actikerall): general benefit
  • Mercaptopurine (Purinethol): general benefit
  • Methotrexate (Methotrexate Sodium): general benefit, Not a benefit
  • Thioguanine (Lanvis): general benefit
  • Fludarabine (Fludara): limited Use 424, 379

Xeloda · DIN 02238453 · 150mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2022-12-07 — choose a marketed DIN from the same-category list.Discontinued 2022-12-07 · checked 2026-09-20
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-12-07 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-12-07 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Xeloda · DIN 02238453 Manufacturer: Hoffmann-La Roche Limited; listing date 2001-06-07 Health Canada: Cancelled post market since 2022-12-07 · brand XELODA · ATC L01BC06 CAPECITABINE · form Tablet · route Oral · ingredients CAPECITABINE 150 MG · company Cheplapharm arzneimittel gmbh · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.4575 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61873 · Verify on the e-Formulary ↗ (DIN 02238453)

Source record
DIN 02238453: Xeloda Raw flags: sec3=Y Item: 100000136; group id 149; item number 0252; lccId None; manufacturer id HLR Source form: Tab; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $1.9478; ministry $0.4575 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02238453 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61873
Interchangeable products
Ach-Capecitabine · DIN 02426757 · $0.4575 Capecitabine · DIN 02514982 · $0.4575 Capecitabine · DIN 02519879 · $0.4575 Sandoz Capecitabine · DIN 02421917 · $0.4575 Taro-Capecitabine · DIN 02457490 · $0.4575 Teva-Capecitabine · DIN 02400022 · $0.4575
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2022-12-07 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

FLUOROURACIL & SALICYLIC ACID

· 1 products · General benefit · strengths: 0.5% w/w & 10% w/w · Top Sol

MERCAPTOPURINE

· 2 products · General benefit · strengths: 50mg · Tab

METHOTREXATE

· 34 products · General benefit (29), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 20mg/2mL, 50mg/2mL, 10mg/0.2mL, 12.5mg/0.25mL, 15mg/0.3mL, 17.5mg/0.35mL, 20mg/0.4mL, 22.5mg/0.45mL, 25mg/0.5mL, 2.5mg, 10mg · Inj Sol-2mL Pk, Inj Sol-Pref Syr, Tab

THIOGUANINE

· 1 products · General benefit · strengths: 40mg · Tab

FLUDARABINE PHOSPHATE

· 1 products · Limited Use, codes 424, 379 · strengths: 10mg · Tab

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

ANASTROZOLE

· 17 products · General benefit · strengths: 1mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab

CHLORAMBUCIL

· 1 products · General benefit · strengths: 2mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications Caution: Sandoz Capecitabine (capecitabine tablets) is a potent drug and should be prescribed only by physicians experienced with cancer chemotherapeutic drugs. Sandoz Capecitabine (capecitabine tablets) is indicated for: Colorectal Cancer Monotherapy • Sandoz Capecitabine (capecitabine tablets) is indicated for the adjuvant treatment of patients with stage III (Dukes’ stage C) colon cancer. • Sandoz Capecitabine is also indicated for the first-line treatment of patients with metastatic colorectal cancer. Combination Therapy Sandoz Capecitabine in combination with oxaliplatin is indicated for the treatment of metastatic colorectal cancer following failure of irinotecan-containing combination chemotherapy. In second-line metastatic disease, subgroup analyses for PFS and OS for age suggest that capecitabine in combination with oxaliplatin may be less effective in patients over the age of 65. Clinical studies suggest an increase in the incidence of adverse events. See 14 Clinical Trials and 7 Warnings and Precautions. Breast Cancer Monotherapy Sandoz Capecitabine is also indicated for the treatment of advanced or metastatic breast cancer afte… https://pdf.hres.ca/dpd_pm/00084234.PDF PM date: not printed or not captured Source product: SANDOZ CAPECITABINE; DIN 02421917; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.